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Background: The interaction between cadherin 17 and 21 integrin promotes cell adhesion and proliferation.
Results: Cadherin 17 contains an RGD motif that constitutes the critical switch for integrin binding and activation.
Conclusion: The cadherin RGD motif is a critical ligand for tumor growth and metastasis.
Significance: Cadherin 17 is the first known integrin-ligand RGD-cadherin. Other RGD-cadherins might play important roles
in cancer metastasis.
Little is known about themechanism of integrin activation by
cadherin 17 (CDH17). Here we observed the presence of a tri-
peptidemotif, RGD, in domain 6 of the humanCDH17 sequence
and other cadherins such as cadherin 5 and cadherin 6. The use
of CDH17 RADmutants demonstrated a considerable decrease
of proliferation and adhesion in RKO and KM12SM colon can-
cer cells. Furthermore, RGD peptides inhibited the adhesion of
both cell lines to recombinantCDH17domain6.TheRGDmotif
added exogenously to the cells provoked a change in1 integrin
to an active, high-affinity conformation and an increase in focal
adhesion kinase and ERK1/2 activation. In vivo experiments
with Swiss nudemice demonstrated that cancer cells expressing
the CDH17 RADmutant showed a considerable delay in tumor
growth and liver homing.CDH17RGDeffectswere also active in
pancreatic cancer cells. Our results suggest that 21 integrin
interacts with two different ligands, collagen IV and CDH17,
using two different binding sites. In summary, the RGD binding
motif constitutes a switch for integrin pathway activation and
shows a novel capacity of CDH17 as an integrin ligand. This
motif could be targeted to avoid metastatic dissemination in
tumors overexpressing CDH17 and other RGD-containing
cadherins.
Cadherin 17 (CDH17), also known as liver-intestine cad-
herin, is a non-canonical, 7D-domain cadherin. Its sequence is
formed by seven extracellular domains and a very short cyto-
plasmic domain (1). CDH17 is present in the fetal liver and
gastrointestinal tract, exhibiting elevated expression during
embryogenesis (2). The gene is silenced in the adult healthy
liver and gut. However, CDH17 is expressed again in gastric
cancer, esophagus carcinoma, pancreatic cancer (3), and hepa-
tocarcinoma (4). In primary colon cancer tumors, poorly differ-
entiated tumors, and lymph nodes, CDH17 is expressed at low
levels (5). However, CDH17 expression is increased in patients
with metastasis and is correlated with a poor prognosis, sug-
gesting an association between CDH17 expression and final
hepatic colonization during late stages of metastasis (6, 7).
CDH17 expression was increased in highly metastatic
KM12SM colon cancer cells (8). An exhaustive proteomic anal-
ysis of cell membrane proteins in these cells detected only five
integrin subunits: 2, 6, v, 1, and 4 (8). No expression of
other integrins in epithelial colon cancer cells has been
described, except for some 6 integrin constructs. CDH17 was
part of a large protein complex containing, among other pro-
teins, 21 and 64 integrins in colorectal cancer cells (7).
After immunoprecipitation of CDH17, only 2, 6, 1, and 4
were found, but not v. Although 64 integrin was present in
the complex, only the interaction with 21 triggered the
integrin signaling pathway and caused the activation of the
focal adhesion kinase (FAK),5 Ras, ERK1/2, and cyclin D1 to
increase cell adhesion and proliferation. In agreement with our
data, it has been described that 2 integrin mediates collagen
type IV-dependent activation of FAK and mediates selective
liver metastasis (9). We also noticed strong binding of
KM12SM cells to collagen IV but not to collagen type I (7).
Integrins are a well known family of cell adhesion molecules
that serve as receptors for extracellular matrix proteins (10).
The tripeptide RGDmotif is a major recognition site for integ-
rins within some ligands, such as fibronectin or fibrinogen (11,
12). However, although 21 integrin contains an RGD-bind-
ing site, their natural ligands, collagens type I and type IV, used
a different binding sequence (GFOGER) (13) and are classified
as RGD-independent ligands (14, 15). Therefore, the reasons
* This research was supported by grant BIO2012-31023 from the Spanish
Ministry of Economy and Competitiveness, by a grant to established
research groups (AECC), and by grant S2011/BMD-2344/ (Colomics2) from
Comunidad de Madrid and ProteoRed-ISCIII.
1 Supportedbyagrant to established researchgroupsof theAsociaciónEspa-
ñola Contra el Cáncer.
2 Recipient of an FPI fellowship.
3 Recipient of a Juan de la Cierva program grant.
4 To whom correspondence should be addressed: Dept. of Cellular and
Molecular Medicine, Centro de Investigaciones Biológicas (CIB-CSIC),
Ramiro deMaeztu 9, 28040Madrid, Spain. Tel.: 34-91-8373112; Fax: 34-91-
5360432; E-mail: icasal@cib.csic.es.
5 The abbreviations used are: FAK, focal adhesion kinase; Ecd, ectodomain;
DOM6, domain 6; RAD, Arg-Ala-Asp; BCECF-AM, 2,7-bis(2-carboxyethyl)-
5(6)-carboxyfluorescein tetrakis(acetoxymethyl) ester.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 50, pp. 34801–34814, December 12, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
DECEMBER 12, 2014•VOLUME 289•NUMBER 50 JOURNAL OF BIOLOGICAL CHEMISTRY 34801
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
for the presence of the RGD-binding site in 21 integrin and
its role in activation were unclear. Moreover, the capacity of
cadherins to act as integrin ligands in cancer cells was com-
pletely unknown.
Herewe investigated the presence of integrin-binding sites in
CDH17 and discovered the presence of an RGD motif. We
decided to evaluate the role of this motif in the activation of
integrin signaling by CDH17. To this end, we used RAD
mutants of CDH17, recombinant fragments, and synthetic pep-
tides. We provide evidence that CDH17 modulates integrin
activity through this motif, provoking a conformational change
in the 1 subunit of the integrin that increased its affinity.
Experiments with nude mice demonstrated a major role of the
RGD motif in tumor growth and dissemination. This report
describes, for the first time, the capacity of CDH17 to act as an
integrin ligand through an RGDmotif to promote integrin acti-
vation that results in enhanced tumor proliferation.
EXPERIMENTAL PROCEDURES
Cell Lines, Antibodies, andPeptides—KM12SMhuman colon
cancer cells were obtained directly from the laboratory of Dr.
Fidler (MD Anderson Cancer Center). RKO human colon can-
cer cells and the pancreatic cancer cell lines BxPc3, Capan-1,
and PANC1 were purchased from the ATCC. The 786-O kid-
ney clear cell carcinoma cell line was provided byM. J. Calzada
(Hospital de la Princesa, Madrid, Spain). As a control we also
used theMCF7 breast carcinoma cell line and the SK-MEL-103
and A375 melanoma cell lines. All cell lines were used within 6
months of purchase and cultured in DMEM (Invitrogen) con-
taining 10% FCS (Invitrogen) and antibiotics at 37 °C in a 5%
CO2 humidified atmosphere.
The antibodies anti-CDH17 (H-167), anti-CDH6, anti-
CDH5, anti-FAK, anti-RhoGDI, anti-2, anti-1, anti-6, anti-
4, and anti-v integrin were purchased from Santa Cruz Bio-
technology. Anti-pFAK, anti-ERK1/2, anti-pERK1/2, and
blocking anti-1 integrin (Lia 1/2.1) were from Cell Signaling
Technology. Anti-1 integrin specific for high-affinity confor-
mation (HUTS-21) was from BD Biosciences. The synthetic
peptide RGDS was purchased from Sigma. The peptides
RADS, SILRGDYQD (CDH5), RAIRRGDTEG (CDH16), and
VSLRGDTRG (CDH17) were synthesized using solid phase
chemistry with a Focus XC instrument (AAPPtec).
Cloning and Mutagenesis of CDH17, Protein Purification,
and Transfections—CDH17mRNA from the human colorectal
cancer cell line Caco2 was reverse-transcribed by Superscript
III first strand synthesis kit (Invitrogen), and the cDNA was
RT-PCR-amplified using the primers 5-AGCTCGAGGATC-
TGAGTTGATCAATCTGCTTAGTG-3 and 5-CGGGTAC-
CATGAGATGGTTGTTGCTGAAATAG-3 with Advantage
2 polymerase (Clontech). The PCR product was digested with
XhoI and KpnI and cloned into pcDNA3.1. Mutagenesis of
CDH17 to change motif 603RGD605 into RAD was performed
with the QuikChange Lightning site-directed mutagenesis kit
(Agilent Technologies), using the primers 5-GGACATAAG-
CTATTCACTGAGGGCAGACACAAGAGGTTGG-3 and
5-CCAACCTCTTGTGTCTGCCCTCAGTGAATAGCTT-
ATGTCC-3. The presence of the mutation was confirmed by
DNA sequencing. Cells were transiently transfected with
CDH17 WT or CDH17 RAD in pcDNA3.1 using JetPrime
(Polyplus Transfection). After 48 h, a fraction of the transfect-
ants was lysed and analyzed by Western blotting to assess the
expression of CDH17. Control siRNA and siRNA against
CDH17 (SASI_Hs01_00166354) were from Sigma-Aldrich.
The recombinant ectodomains of CDH17 (WT and RAD
mutant) were expressed with the baculovirus system in insect
cells according to standard procedures. Recombinant domains
6 (WT andmutant) were produced in Escherichia coli and puri-
fied according to standard procedures (16).
Reverse Transcription PCR—For CDH6 and CDH20 amplifi-
cation, cells were lysed in TRIzol reagent (Ambion). RNA was
extracted and reverse-transcribed using MoMLV reverse tran-
scriptase (Promega). Amplification of CDH6 was done by PCR
using primers 5-GTCATCACCGACCAGGAAAC-3 and 5-
TGCAGGGTCTGAATCAACTG-3. For CDH20, the primers
were 5-AGAGGAGCTGGGTTTGGAA-3 and 5-GCATCT-
GTGGCTGTCACTTG-3. The PCR profile was 33 cycles of
30 s at 94 °C, 30 s at 56 °C, and 45 s at 72 °C with TaqDNA
polymerase (Invitrogen).
Cell Adhesion and Soluble BindingAssays—For cell adhesion,
96-well plates were coated with Matrigel (4 l/ml) (BD Biosci-
ences) or type IV collagen (5g/ml) (Sigma-Aldrich) in coating
buffer (0.1 M NaHCO3 (pH 8.8)) for 20 h and incubated with
adhesion medium (0.4% BSA in serum-free DMEM) for 2 h to
block unspecific binding. Cell were starved for 5 h without
serum, labeled with BCECF-AM (Invitrogen), detached with 2
mM EDTA in PBS, and resuspended in serum-free DMEM, and
then 7 104 cells in 100l were added to plates in triplicate and
incubated for 25 min. Non-adherent cells were removed by
three washes with DMEM. Bound cells were quantified using a
fluorescence analyzer (POLARstar Galaxy).
For soluble binding assays, cells were detached, incubated for
40 min with CDH17 ectodomain (10 g/ml) at 37 °C in Ca2-,
Mg2-, and Mn2-free Hanks’ balanced salt solution medium
(Invitrogen), washed, incubatedwith anti-CDH17 antibodies at
4 °C, washed again, incubated with secondary antibodies, and
analyzed by flow cytometry. For cell adhesions to CDH17
domain 6 (2–10 g/ml), adhesion assays in 96-well microtiter
plateswere performed as above but inmediumcontaining 1mM
MnCl2, and cells were washed gently using a multi-channel
pipette. For blocking assays, cells were preincubated with
anti-1 integrin (5 g/ml) for 10 min before adhesion.
Affinity Chromatography for 21 Integrin—1mg of purified
CDH17 domain 6 WT was coupled to a HiTrap NHS 1 ml
column (GE Healthcare). KM12SM cell extracts (20 mg) were
loaded into the column, incubated for 10min, and washed with
10ml of lysis buffer at a flow rate of 0.4 ml/min using an ÄKTA
system. Elution was performed with 5 ml of 1.5 mM RGDS
peptide.
Cell Separation—Magnetic beads coated with protein G
(Invitrogen) were incubated with 10 g of anti-2 integrin for
1 h at 4 °C. 4  105 RKO cells, knocked down or not knocked
down for2 integrin, were resuspended in 0.5%BSA in PBS and
incubated for 40 min at 4 °C with the coated beads. Cells were
separated magnetically, and each population was subjected to
Western blot analysis using anti-2 integrin antibodies to
assess the efficacy of isolation.
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FIGURE 1. Sequence analysis of the cadherin protein family reveals a RGDmotif in several cadherins. A, the different genes of human cadherin families.
The presence of RGDmotifs is indicated. B, structure of five cadherins containing RGDmotifs (right) and the flanking sequences of suchmotifs (left). C, CDH16,
CDH6, and CDH20 were not detected, and CDH5 was barely detected in KM12SM and RKO cells by Western blot analysis (CDH5 and CDH16) or PCR amplifi-
cation assays (CDH6 andCDH20). As positive controlsweusedbreast cancer (MCF7), kidney clear cell carcinoma (786-O), and SK-MEL-103 andA375melanoma
cell lines. D, according to Jpred3, domain 6 of CDH17matchedmost significantly (Blast E-value 7 1010) with domain 2 of CDH1 (PDB code 3Q2V) in PDB
modeling. Alignment of the domains showed that the RGDmotif of CDH17matchedwith exposedWRD residues (372–374) in CDH1. E, according to NetSurfP
protein surface accessibility and secondary structure predictions software, the three amino acids of the RGDmotif in CDH17 were exposed.
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Flow cytometry—Cells were detached with 2 mM EDTA in
PBS, incubated at 4 °C with primary antibodies (10 g/ml) for
30 min, washed, and incubated with Alexa Fluor 488-labeled
secondary antibodies (anti-mouse IgG or anti-rabbit IgG,
Dako). Fluorescence was analyzed in a Coulter Epics XL cyto-
fluorometer. Mean fluorescence intensities for the indicated
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antibodies are shown in each figure. As a reference, irrelevant
control antibodies (anti-cadherin-11, Santa Cruz Biotechnolo-
gies) gave a mean fluorescence intensity of 0.3.
Cell Aggregation Assays—105 Cells were detached with 2 mM
EDTA in PBS, resuspended in 100l of DMEM, and allowed to
aggregate for 30 min at 37 °C with constant shaking at 30 rpm.
Total cells and cells forming aggregates were counted under a
microscope in five different fields.
Proliferation Assays—Cells were seeded at 1 104 cells/well
on 96-well plates and incubated for 24–48 h at 37 °C in DMEM
with 0.5% serum, followed by 1 h incubation with 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (0.6
mg/ml, Sigma-Aldrich). Cell proliferation was determined
by absorbance at 560 nm and compared with control cells
collected at time 0.
Western Blot Analysis and Immunoprecipitation—Cells were
starved for 4 h and allowed to bind to domain 6 of CDH17-
coated plates for 45 min. Then, cells were detached, washed,
and lysed with 1% Igepal, 100 mM NaCl, 2 mM MgCl2, and 10%
glycerol in 50 mM Tris-HCl containing proteases and phospha-
tases inhibitors. Protein extracts were separated in SDS-PAGE
gels, transferred to nitrocellulose membranes, and incubated
with primary antibodies (1g/ml), followed by incubation with
either HRP anti-mouse IgG (Thermo Scientific) or HRP anti-
rabbit IgG (Sigma-Aldrich). Reactive proteins were visualized
with SuperSignal West Pico chemiluminescent substrate
(Thermo Scientific). Densitometric analyses were carried out
using Quantity One (Bio-Rad). For immunoprecipitation, cells
were lysed, and 500 g of cell lysate was incubated with the
indicated antibodies (5 g/ml). The immunocomplexes were
captured by adding 50l of proteinG-Sepharose beads (Sigma-
Aldrich). After washing, samples were resuspended in loading
buffer, boiled for 5 min, centrifuged, and subsequently loaded
on 10% SDS-PAGE gels for Western blot analysis.
Immunohistochemistry—A total of 48 patients diagnosed and
treated for pancreatic cancer in Fundación Jiménez Díaz
(Madrid, Spain) between 2003 and 2013 were used for the
study. Informed written consent was obtained from all partici-
pants, as required and approved by the Research Ethics Com-
mittee of theHospital Fundación JimenezDiaz (Madrid, Spain).
Samples were fixed and stained as described previously (7).
In Vivo Assays—In vivo assays were performed using Swiss
nude mice (Charles River Laboratories). The Ethical Commit-
tee of the Consejo Superior de Investigaciones Científicas
(Madrid, Spain) approved the protocols used for experimental
work with mice. Liver homing assays were performed as
described previously (17). Briefly, 106 cells, KM12SM or RKO,
transfected with vectors encoding for CDH17 WT, RAD, or
empty vectors (mock) were inoculated intrasplenically into
mice (n  3), which were euthanized after 24 h. RNA was iso-
lated frommouse livers using TRIzol and retrotranscribed. The
cDNA was subjected to 30 cycles of PCR with TaqDNA poly-
merase to amplify human GAPDH, a housekeeping gene. As a
loading control, amplification of murine -actin was per-
formed. For xenografts, tumors were induced by subcutaneous
injection of 5  106 cells, KM12SM or RKO, in PBS with 0.1%
glucose into nudemice (n 3). After 10 days, mice were eutha-
nized, and tumors were excised and weighed.
Statistical Analyses—Data were analyzed by one-way analy-
sis of variance followed by Tukey-Kramermultiple comparison
test. In both analyses, the minimum acceptable level of signifi-
cance was p 0.05.
RESULTS
The Human CDH17 Sequence Contains an RGD Motif—
After revising the sequence of 31 human cadherin genes (Fig.
1A), an RGD motif was found in an extracellular domain of
CDH17 and CDH16. Other cadherins containing RGD motifs
were VE-cadherin (CDH5), fetal kidney K-cadherin (CDH6),
and CDH20. All of them are classified as type II atypical cad-
herins (Fig. 1A). The RGD motif was present in domain 6 of
CDH17 and domain 5 of CDH16 (Fig. 1B). Analysis of CDH17
orthologs showed that the RGD motif in CDH17 was exclu-
sively present in somemammals (data not shown). For instance,
mouse CDH17 does not contain an RGD motif. The flanking
sequences of RGD (Fig. 1B) are different from other reported
consensus sequences for integrin ligands, like fibronectin (18).
To discard additional cadherins in our colon cancer cells, we
tested the expression of other RGD cadherins either by West-
ern blot analysis or PCR. RKO and KM12SM cells did not
express CDH6, CDH16, or CDH20. CDH5 was barely detected
in KM12SM cells but not in RKO cells (Fig. 1C). Breast, kidney,
and melanoma cancer cells were used as positive controls.
The structure of CDH17 is unknown, but the RGD motif is
predicted to be exposed using two different bioinformatic
approaches. According to Jpred 3 (19), CDH17 domain 6
matched most significantly with the known structure of CDH1
domain 2. The alignment of both domains showed that the
RGD motif matched exposed WRD residues (372–374) in
CDH1 (Fig. 1D). Accordingly, NetSurfP software (20), which
calculates the surface accessibility of protein residues, pre-
dicted an exposition of the RGD motif in CDH17 (Fig. 1E).
These predictions suggest the accessibility of the RGDmotif for
protein-protein interactions.
MutationofRGDinCDH17ReducesAdhesionandProliferation
in Colorectal Cancer Cells but Does Not Affect Aggregation—
To examine the effect of the RGD motif on colorectal cancer
cells, vectors encoding for wild-typeCDH17 (CDH17-WT) or a
FIGURE 2.Thepresenceof CDH17RGD is required for the increase in cell adhesionandproliferation.A and B, RKOandKM12SMcellswere transfectedwith
vectors encoding for CDH17WT, amutant form (CDH17 RAD), or empty vectors (Mock). Transfectants were analyzed byWestern blotting (A) or flow cytometry
(B) to assess the expression of CDH17 in whole lysates and cell membranes, respectively. C, RKO transfectants were subjected to cell aggregation assays.
Representative pictures and a quantification of cell forming aggregates are shown.D, transfectants were subjected to cell adhesion assays on collagen type IV
orMatrigel. Adhesionwas enhanced significantly by overexpression of CDH17wild-type or decreasedby silencing of endogenous CDH17. **,p 0.01; ***, p
0.001. E, RKOandKM12SMwere transfectedwith siRNAs for the indicated integrin subunits orwith a control siRNA. After 48h, transfectantswere lysed, and the
extracts were analyzed by immunoblotting to assess the interference in the expression. Anti-RhoGDI was used as a loading control. F, KM12SM transfectants
were subjected to cell adhesion assays on Matrigel. Cell adhesion was inhibited significantly by silencing of the indicated proteins. ***, p  0.001). G,
transfectants were incubated in 0.5% serum for 48 h and subjected to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Cell proliferation
was increased significantly by overexpression of CDH17 WT or decreased by silencing of endogenous CDH17. **, p 0.01.
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FIGURE 3. The CDH17 RGDmotif is a ligand of 21 integrin. A, binding of 21 integrin to immobilized CDH17 DOM6WT. KM12SM cells were lysed and
loaded onto a 1-ml column of CDH17 domain 6 WT coupled to agarose. After extensive washing, the column was eluted with RGDS peptide. The fractions (1
ml) were precipitated and subjected toWestern blot analysis using anti-2 and anti-1 integrin antibodies. RGDS elution started at fraction number 7. B, RKO
and KM12SM cells transfected with vectors encoding for CDH17WT, CDH17 RAD, or empty vectors (Mock) were lysed, subjected to immunoprecipitation (IP)
with anti-2 integrin or anti-CDH17 antibodies, and analyzed by Western blotting with the indicated antibodies. C, expression of v integrin in RKO and
KM12SM cells, detected byWestern blot analysis (left panel) and immunoprecipitation assayswith anti-v integrin, anti-CDH17, or control antibodies showing
the lack of association between this integrin subunit and CDH17 (right panel). D, polyacrylamide gels stained with Coomassie Blue showing the expression of
purified Ecd (left panel) or of purified domain 6 (DOM6, right panel) of CDH17, both theWT or themutant lacking the RGDmotif (RAD). E, soluble binding assays
using the CDH17 ectodomain as a ligand. Flow cytometry showed that, after incubation with the wild-type ectodomain, this protein fragment was bound to
the cell surface. Mean fluorescence intensity is indicated. F, soluble binding assays using the CDH17 ectodomain as ligand in cells silenced for the indicated
integrin subunits. Mean fluorescence intensity is indicated for both CDH17 ectodomain WT and RAD.
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RAD mutant (CDH17-RAD) were used to transfect KM12SM
and RKO human colorectal cancer cells. Poorly differentiated
RKO cells are non-metastatic cells that do not express CDH17,
whereas KM12SM cells are highly metastatic colon cancer cells
expressing CDH17 (7). After transfection, wild-type and RAD
mutant CDH17 were overexpressed in both cell lines at similar
levels, as detected byWestern blot analysis and flow cytometry
(Fig. 2, A and B). First, we tested the aggregation of cells
expressingCDH17. RKOCDH17 transfectants showed a signif-
icant increase in cell aggregation in respect to mock cells after
FIGURE 4. The CDH17 RGDmotif is able to mediate cell adhesion. A, RKO and KM12SM cells were subjected to cell adhesion assays in plates coated with
different concentrations of CDH17-DOM6WT or CDH17-domain 6 RAD in the presence of 1 mM MnCl2. Adhesion was increased significantly in plates coated
with CDH17-DOM6WT compared with plates not coated. **, p 0.01. B, cell adhesion assays for CDH17 domain 6WTwere done in the presence of the RGDS
and RADS peptides or anti-1 integrin-blocking antibodies. Adhesion was inhibited significantly by the addition of peptides or antibodies. *, p 0.05; **, p
0.01; ***, p 0.001. C, cell adhesion assays for CDH17 domain 6WTwith cells silenced for the indicated integrin subunits. Adhesionwas inhibited significantly
by the silencing of the indicated integrin subunits. **, p 0.01; ***, p 0.001.
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detachment (Fig. 2C). This increase was RGD-independent
because CDH17 RAD transfectants showed the same increase
in aggregation. This result suggests a homotypic aggregation
capacity for CDH17, as described for other cadherins (21).
Then, we assessed the capacity of the transfectants for cell
adhesion to Matrigel or collagen type IV. Overexpression of
CDH17-WT in both cell lines increased the adhesion to both
types of extracellular matrix (Fig. 2D). In contrast, CDH17-
RAD transfectants showed a basal adhesion, as mock transfec-
tants, suggesting that the RGDmotif was necessary to increase
cell adhesion. Also, CDH17 silencing significantly reduced the
adhesion of KM12SM cells (Fig. 2D). Cell adhesion required
21 integrin but not 64 integrin, as demonstrated by using
siRNAs against each integrin subunit in adhesion assays with
KM12SM cells (Fig. 2, E and F). Finally, cells expressing
CDH17-WT showed a significant increase in proliferation,
whereas the CDH17-RAD mutant was unable to increase cell
proliferation (Fig. 2G). Collectively, these data indicate that the
presence of the RGD motif increased cell adhesion and prolif-
eration in colon cancer cells through21 integrin but does not
affect homotypic aggregation.
The CDH17 RGD Binding Motif Is a Ligand for 21 Integrin—
Previously, we showed that CDH17 and 21 integrin coim-
munoprecipitated together. To prove a direct interaction, we
decided to purify 21 integrin using affinity chromatography
on the basis of the coupling of CDH17 domain 6 WT to Sep-
harose following a similar strategy as Pytela et al. (22).
KM12SM lysates were loaded on the affinity column and
washed extensively, and then the column was eluted with an
RGDS peptide. Both 21 integrin subunits were detected by
Western blot analysis in the eluted fractions, confirming the
integrin binding to CDH17 and the role of the RGD motif in
that binding (Fig. 3A). To confirm that this association was
RGD-dependent, CDH17 was coimmunoprecipitated with
21 integrin in RKOcells after transfectionwithCDH17-WT.
In contrast, transfected CDH17-RAD was not detected after
immunoprecipitation with 2 integrin and vice versa in RKO
(Fig. 3B). The 21 integrin was associated with FAK when
CDH17-RGD WT was present but not after RAD mutation.
Therefore, to start signaling, the binding of the RGDmotif was
critical for the integrin-FAK association. To discard v integ-
rin, we carried out further coimmunoprecipitations. We did
not detect v integrin in CDH17 coimmunoprecipitates and
vice versa (Fig. 3C).
To evaluate whether exogenous CDH17 could be a ligand of
integrins, we used the purified recombinant CDH17 ectodo-
main expressed in baculovirus and the recombinant CDH17
domain 6 (571–665) expressed in E. coli. In addition, we pre-
pared RADmutants of the ectodomain and domain 6 (Fig. 3D).
After incubation, the CDH17 ectodomain bound to the cell
surface (Fig. 3E).However, theRADmutant formof theCDH17
ectodomain was unable to bind to cells. To confirm that this
binding was specific for 21 integrin, we silenced the expres-
sion of the 21 and 64 integrins using siRNAs (Fig. 2D). In
both types of cells, RKO and KM12SM, the silencing of 21
integrin subunits inhibited the binding of theCDH17-RGDect-
odomain. However, the silencing of 64 integrin subunits did
not affect the ability of the CDH17 ectodomain to bind the cell
surface (Fig. 3F).
Then, we tested recombinant domain 6 as a ligand in cell
adhesion assays. We found that 2 and 10 g/ml were the opti-
mal doses in RKO andKM12SMcells, respectively, for promot-
ing cell adhesion to plates coated with domain 6 (Fig. 4A).
Moreover, there was a clear dose-dependent effect of the RGDS
peptide to inhibit cell adhesion toCDH17domain 6WT in both
cell lines. The competition started at 1 M and was similar to
that obtained with a blocking antibody, anti-1 integrin (Fig.
4B). In contrast, the RADS peptide did not inhibit cell adhesion
FIGURE 5. 1 integrin signaling after exposition to CDH17 RGD. A, RKO
andKM12SMcellswere allowed to adhere toplates coatedor not coatedwith
CDH17domain 6WTor RADorwithout protein (control) for 45min. Cellswere
lysed, and the extracts were analyzed by Western blotting with antibodies
against FAK and ERK1/2 and their phosphorylated forms. B, RKO cells were
transfected with vectors encoding for CDH17 WT, RAD mutant, and empty
vectors (mock) andwith siRNAs targeting2 integrin or the control. The com-
binations were as follows: 2 integrin-expressing transfectants (C) were
cocultured with CDH17-expressing transfectants (M, W, and A) for 45 min.
Then, 2 integrin expressing transfectants were isolated using anti-2 integ-
rin antibodies coupled to magnetic beads and analyzed separately. Extracts
fromtransfectantsnot subjected to cocultureswerealsoanalyzedbyWestern
blotting.
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(Fig. 4B). This result suggests that CDH17 domain 6 mediates
cell adhesion in an RGD-dependent manner. Again, to confirm
that the binding was integrin-dependent, we silenced the
expression of the four integrin subunits. Only silencing of21
integrin significantly inhibited cell adhesion to CDH17 domain
6 (Fig. 4C).
Role of the RGD Motif in Integrin Signaling—To assess the
role of theRGDmotif in integrin activation, we treated both cell
lines with CDH17 domain 6WT and the RADmutant. Incuba-
tion with CDH17 domain 6 WT increased phospho-FAK and
phospho-ERK1/2 activity, whereas CDH17 domain 6 RAD did
not (Fig. 5A). To investigate whether signaling pathways could
be directly activated throughCDH17, we prepared four types of
RKO transfectants: control siRNA (C), 2 integrin silenced
(M), expressing CDH17 with 2 integrin silenced (W), and
expressing CDH17 RAD with 2 integrin silenced (A). Control
siRNA transfectants were allowed to interact with the other
transfectants for 45 min. Then, control transfectants were sep-
arated using anti-2 integrin magnetic beads. All transfectants
were lysed separately and subjected toWestern blotting to ana-
lyze the activation of several signaling proteins, such as FAK,
ERK1/2, Akt, and Src. FAK and ERK1/2 were activated only in
control transfectants (expressing 2 integrin) cocultured with
transfectants expressing CDH17 with 2 integrin silenced
FIGURE6.RGDenhances1 integrin activationandcell adhesion toMatrigel.A, RKOandKM12SMcellswere transfectedwith vectors coding toCDH17WT
orRADorwith empty vectors (mock) for 45minand subjected to flowcytometry assayswithHUTS21antibody,which recognizes1 integrin in thehigh-affinity
conformation, or with a control antibody. Mean fluorescence intensity is indicated. B, RKO and KM12SM cells were exposed to CDH17 DOM6 (2g/ml) or Ecd
(10g/ml) (WT or RAD) ormedium for 45min and subjected to flow cytometry assayswith HUTS21 antibody or a control antibody as inA. C, RKO and KM12SM
cellswere exposed tonine amino acid peptides (0.5g/ml), whose sequences include the RGDmotif and flanking amino acids belonging toCDH5, CDH16, and
CDH17, for 45min and subjected to flow cytometry as inA.D, after incubationwith CDH17DOM6or Ecd (WT or RAD), cells were collected and subjected to cell
adhesion assays on Matrigel. Adhesion was enhanced significantly by incubation with CDH17 DOM6WT or Ecd WT. **, p 0.01; ***, p 0.001.
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(Fig. 5B). In contrast, transfectants expressing CDH17, with 2
integrin silenced cocultured with control transfectants, did not
show activation of any of these proteins (Fig. 5B). Therefore,
signaling activation was triggered exclusively through the
integrin, whereas CDH17 was unable to signal into the cell.
Collectively, these data confirmed that the RGDmotif was crit-
ical for the activation of the integrin-triggered proliferation
cascade.
Role of the RGD Motif in 1 Integrin Activation—To assess
the role of the RGDmotif in integrin activation, we transfected
both cell lines with vectors containing CDH17 WT and the
RAD mutant. Expression of 21 integrin was not affected by
altering CDH17 expression levels in colorectal cancer cells (7).
However, CDH17-WT increased the high-affinity conforma-
tion of 1 integrin in RKO and KM12SM cells, as shown by
using the HUTS21 antibody, which specifically recognizes this
conformation (Fig. 6A). In contrast, cells transfected with
CDH17-RAD showed similar amounts of high-affinity confor-
mation 1 integrin as mock cells (Fig. 6A). Therefore, the RGD
motif in CDH17 provoked the change to the high-affinity con-
formation required for 1 integrin activation. In the same way,
preincubation with the CDH17 ectodomain or domain 6 WT
enhanced the amount of1 integrin in the high-affinity confor-
mation, whereas incubation with the RAD mutants had no
effect (Fig. 6B). In addition, we tested the effect of the RGD
flanking sequences on integrin activation. Besides the CDH17
peptide, we tested the CDH16 and CDH5 RGD flanking
sequences. Exposition to the CDH17 peptide increased high-
affinity conformation 1 integrin in both cell lines (Fig. 6C). A
similar effect was observed when cells were exposed to the
CDH5 RGD peptide (Fig. 6C). In contrast, CDH16 RGD had no
effect on 1 integrin activation (Fig. 6C). These results confirm
the relevance of the RGD flanking sequences on 1 integrin
activation.
Finally, we assessed whether the change to the high-affinity
conformation of 1 integrin increased the adhesive capacity of
the cells. The CDH17 ectodomain and domain 6 WT caused a
significant increase in cell adhesion to Matrigel, whereas the
RAD mutant hardly increased the basal levels (Fig. 6D).
The CDH17 RGD Motif Is Critical for Tumor Growth and
Metastasis—We carried out subcutaneous and intrasplenic
inoculations of Swiss nudemicewith RKOandKM12 cells con-
taining CDH17 WT or mutant RAD in triplicate. Mice were
sacrificed 24 h after intrasplenic injection of cells, and livers
were collected for DNA extraction and PCR analysis (Fig. 7A).
Liver DNA from mice inoculated with CDH17-RGD cells was
positive by PCR using human GAPDH primers. In contrast,
mice inoculated with CDH17-RADmutant cells showed negli-
gible DNA amplification in the liver. After subcutaneous inoc-
ulation, CDH17 WT cells developed considerable tumors. In
contrast, cells containing RAD mutants showed very small
tumors, similar to the control (Fig. 7B). Tumor weight corrob-
orated these differences between CDH17-RGD and RAD cells
(Fig. 7B). These results support a critical role for the RGDmotif
in the tumor growth and metastatic dissemination in colon
cancer.
The CDH17 RGD Motif Is Relevant in pancreatic Cancer
Cells—CDH17 overexpression has been reported in some pan-
creatic tumors (3). Here, in a sample set of 48 patients with
pancreatic cancer, we detected CDH17 expression in 60.4% of
tumors by immunohistochemistry. Among CDH17-positive
tumors, 62.1% showed intense staining, indicating overexpres-
sion of CDH17 (Fig. 8A). To learn whether our findings could
be extended to pancreatic cancer, we used the BxPC3, PANC-1,
and CAPAN pancreatic cancer cell lines. PANC-1 and CAPAN
cells showed expression of CDH17, but BxPC3 did not (Fig. 8B).
After transfection with CDH17-WT and CDH17-RADmutant
vectors, we observed clear differences in adhesion capacity.
Although CDH17-WT caused a clear increase in the three cell
lines, the RAD mutant failed to increase adhesion above basal
levels (Fig. 8C). Moreover, cell proliferation increased in
CDH17-RGD transfectants but not in cells transfected with
CDH17-RAD (Fig. 8D). These results support an extension of
our findings to other cancers expressing CDH17, like pancre-
atic cancer.
FIGURE 7. The RGDmotif is critical for tumor growth and metastatic dis-
semination. A, Swiss nudemicewere inoculated intrasplenically with RKO or
KM12SM cells transfected with vectors encoding for CDH17WT, CDH17 RAD,
or empty vectors (Mock). Human GAPDH was RT-PCR-amplified from RNA
isolated from the livers 24 h after inoculation. Amplification ofmurine-actin
was used as a control. B, the same transfectants were inoculated subcutane-
ously. Top panel, representative picture of tumors developed after 10 days.
Bottom panel, tumor weight after 10 days was increased significantly in cells
expressing CDH17 WT. *, p 0.05.
The CDH17-RGDMotif Is Critical for Integrin Activation
34810 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 50•DECEMBER 12, 2014
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
DISCUSSION
We found that the human 7D-cadherin, CDH17, contains an
RGDsitewith the capacity to act as a new ligand for integrin bind-
ing. This conclusion was obtained from the following observa-
tions. Interaction ofCDH17with21 integrin required the pres-
ence of the RGD binding site; the capacity of the RGD motif to
specifically bind21 integrin in colon cancer cellswas supported
by different binding and cell adhesion assays, including siRNA
experiments; theCDH17-RGDectodomainwasable tobindcolon
cancer cells and activate 1 integrin when added exogenously;
and, after in vivo inoculation, tumor cells expressing mutant
CDH17 RAD showed a considerable delay in tumor growth and
liver colonization. In summary, RGDworks as a switch that regu-
lates the integrin activation in colon cancer metastatic cells.
FIGURE 8.CDH17expressionpromotes cell adhesionandproliferation inpancreatic cancer cells.A, immunohistochemistry analysis of CDH17 expression
in human pancreatic cancer samples (n 48) showing representative images of strong, moderate, or negative staining and the percentage in each classifica-
tion. B, BxPc3, Capan-1, and PANC-1 cells were transfected with vectors encoding for CDH17 WT, CDH17 RAD, or empty vectors (Mock). Transfectants were
lysed, and the extractswere subjected toWesternblot analysis to confirm theoverexpressionof CDH17.C, transfectantswere subjected to cell adhesion assays
onMatrigel. Adhesion was enhanced significantly by overexpression of CDH17WT. **, p 0.01; ***, p 0.001.D, transfectants were incubated in 0.5% serum
for 24 h and subjected to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide assays. Cell proliferationwas increased significantly by overexpression
of CDH17 WT. **, p 0.01; ***, p 0.001. As a control, a fraction of the cells was subjected to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assays at time 0.
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FIGURE 9. Proposed models for the interaction between CDH17 and 21 integrin. A and B, either CDH17 of a contiguous cell (A) or the soluble CDH17
ectodomain (B) can modulate the binding of 21 integrin to collagen type IV. C, medium conditioned for 24 h from KM12SM was collected, concentrated,
resolved by SDS-PAGE, and in-gel-digestedwith trypsin.Mass spectrawere acquired on an LTQ-Orbitrap Velosmass spectrometer, and the fileswere searched
against the SwissProt database using theMASCOT search engine. Peptides assigned to CDH17 aremarked in red in the sequence of CDH17 (right). All detected
peptides belong to the ectodomain (domains 1–7) of CDH17 (left). 32% of the ectodomain was detected by the proteomics analysis.
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CDH17, as other cadherins, can mediate cell-cell interac-
tions by homotypic binding (21). In fact, RKO transfectants
showed an increase in cell aggregation after cell detachment.
The aggregationwas not RGD-dependent, suggesting a CDH17
homotypic interaction different from integrin-cadherin inter-
action. Binding assays in the absence of divalent cations
indicated that the RGD-containing CDH17 ectodomain was
sufficient to mediate binding to the integrin. Moreover, coim-
munoprecipitation assays showed that CDH17-21 integrin
interaction was quite stable in the presence of different deter-
gents (1% of digitonin, Igepal, or Triton X-100). Only cell adhe-
sion to CDH17 DOM6 RGD-coated plates required the pres-
ence of manganese, indicating that the interaction was
relatively weak when this domain was used as a substrate in
coated plates. In any case, integrin activation, including activa-
tion of FAK and ERK proteins, in cells bound to the wild-type
CDH17 domain 6 (in the absence of divalent cations) was com-
parable with the activation in cells adhered to collagen. There-
fore, the CDH17-21 integrin binding works as a functional
interaction between a ligand and its receptor, which triggers the
integrin signaling pathway.
Other integrins, different from 21 integrin, have been
classified as RGD receptors (23); for instance, combinations of
1 with 5, v, or 8 or combinations of v with 3, 5, 6, or
8 (24). However, apart from 1, from these possible combina-
tions, only v integrin was detected in KM12SM cells after pro-
teomic analyses, and we proved that was not associated with
CDH17 (Fig. 3B). Only 21 integrin was required for binding
to CDH17 in KM12SM and RKO cells, but not 64 integrin.
64 integrin is a receptor for laminins, and the binding motif
in laminins is still unknown, but it seems to be RGD-indepen-
dent. Therefore, althoughwe do not discard the hypothesis that
CDH17might bind other integrins (i.e.v6) in other cell lines,
we provide strong evidence that 21 integrin is the only
binder of CDH17 in KM12SM and RKO colon cancer cells.
On the basis of our results,21 integrin should work simul-
taneously as a receptor RGD-dependent for CDH17 and RGD-
independent for collagen IV, suggesting a simultaneous binding
cooperative effect of both cadherin and collagen in the fine-
tuning of 21 integrin activation (Fig. 9, A and B). In recent
reviews (Ref. 23 and later), integrins have been divided in sev-
eral groups, those that work as collagen receptors (GFOGER),
i.e. 21 integrin, or those that work as RGD receptors
(fibronectin, etc.), i.e. v3 or 51. In light of our results with
21 integrin and RGD cadherins, this classification should be
reevaluated, and these two groups should probably be com-
bined into one because both groups work as RGD receptors but
with different ligands. In fact, 21-mediated adhesion to col-
lagen can be inhibited by an RGD-containing cyclic peptide
(23).
Another relevant question is whether the cadherin/integrin
interaction takes place in cis or in trans. The transmodel would
require the presence of CDH17 on the surface of a contiguous
cell (Fig. 9A) or the presence of soluble ectodomains of CDH17
(Fig. 9B) to facilitate the contact in the interface of 2 and 1
subunits, which is the ligand recognition site. Our data suggest
that an interaction in trans is more probable because incuba-
tion with the soluble recombinant ectodomain, followed by
integrin activation, would mimic the interaction with the solu-
ble formof CDH17 after shedding of thismolecule from the cell
surfacemembrane. Furthermore, the coculture of cells express-
ing only CDH17with cells expressing only2 integrin reflects a
trans interaction between two cells. Still, an interaction in cis
cannot be totally ruled out.
Other cadherins, like CDH5 (which contains two RGD
motifs), CDH6, or CDH20, also contain RGD-binding sites, and
they could play important roles in cancer metastasis in other
cancer types, where they are overexpressed. Here we provide
evidence that CDH5 RGD, but not CDH16, also activates 21
integrin. Therefore, the flanking sequences of the cadherin
RGDmotif strongly influence the binding capacity to integrins
and confer specificity to the interaction. In agreement with this
hypothesis, recent studies point out a role for these cadherins in
cancer and vascular damage. CDH5 and CDH6 seem to pro-
mote cancer progression (25), thrombus formation, and vascu-
lar injury because of the induction of platelet aggregation (26).
Some studies have reported an up-regulation of CDH5 in inva-
sive human breast tumors and in a breast cancer model (25),
andCDH5 inductionwas responsible for vasculogenicmimicry
in aggressive melanomas (27). In platelets, a previous study
revealed a role for CDH6 as a novel ligand for IIb3 integrin,
this binding being responsible for platelet aggregation and
thrombus formation (26). This interaction might play a role in
the signs of thrombosis occurring in patients at the metastatic
stage and the contribution of platelets to tumormetastasis (28).
Further experiments are required to clarify the integrin-bind-
ing capacity as a general mechanism of RGD-containing cad-
herins for the promotion of metastasis.
CDH17, as other cadherins, is a target for ectodomain shed-
ding because of the presence of elevated protease activity in the
tumor microenvironment. Previous observations confirmed
the shedding of CDH17 in the conditioned medium of
KM12SM cells (29). The secreted soluble form of CDH17 con-
tained the RGD domain. This shedding in metastatic cells
makes CDH17 a candidate biomarker for detection in biofluids
(serum or plasma) of colon cancer patients. Therefore, CDH17
could be useful for patient stratification and targeted therapy.
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